MREO
Mereo BioPharma Group plc
$0.3050
-2.24%
$47.3M
No data for this timeframe.
Vol
Market Cap$47.3M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (71%)
Inst. Holders22 funds
Inst. Value$8.6M
Inst. Activity1 buys / 2 sells
Reddit Sentiment75° Bullish
SEC Reports2
Press Releases1
Recent Activity
Jun 11, 2026
SEC
Institutional cluster shows net accumulation in MREO during 2025-Q3, with 4 buyers adding $10.4M and 1 seller reducing $
INST-CLUSTER — Impact 4/10
Jun 2, 2026
short_volume
Short Volume: MREO — 60.3% short (3.0M / 5.0M)
Short: 3,027,630 | Exempt: 376,275 | TRF Vol: 5,019,059 | Short Ratio: 60.3% | Off-exchange volume (
May 12, 2026
SEC
Mereo BioPharma reported Q1 2026 EPS of -$0.01, missing the $0.00 consensus estimate, with revenue not explicitly stated
PRESS-RELEASE — Impact 6/10
Feb 26, 2026
Insider
Jacquet Pierre was granted 66,000 shares
Director
Feb 26, 2026
Insider
Jacquet Pierre was granted 106,848 shares
Director
Feb 26, 2026
Insider
Bender Jeremy was granted 66,000 shares
Director
Inst.
BANK OF AMERICA CORP — DOUBLED
8,195,287 shares ($2.7M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — NEAR_EXIT
48,400 shares ($16.0K)
Price Targets
$1.73
+467.7% upside
Strong Buy
Current $0.3050
Low $0.4982
Median $1.48
High $2.98
6 analysts
$0.4982
$2.98
Analyst Ratings
5Strong Buy
5Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 12, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 23, 2026 | JP Morgan | DOWNGRADE | Overweight → Neutral |
| Jan 16, 2026 | BTIG | REITERATE | Buy → Buy |
| Jan 13, 2026 | Needham | MAINTAIN | Buy → Buy |
| Dec 30, 2025 | Jefferies | DOWNGRADE | Buy → Hold |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.01 | $-0.01 — $0.00 | 62% YoY | 5 |
| Next Q | $-0.01 | $-0.01 — $-0.01 | 8% YoY | 5 |
| Current FY | $-0.03 | $-0.04 — $-0.02 | 25% YoY | 5 |
| Next FY | $-0.03 | $-0.04 — $0.01 | -0% YoY | 6 |
Latest Reports
NEUTRAL
INST-CLUSTER
4/10
Institutional cluster shows net accumulation in MREO during 2025-Q3, with 4 buyers adding $10.4M and 1 seller reducing $
Jun 11, 2026
BEARISH
PRESS-RELEASE
6/10
Mereo BioPharma reported Q1 2026 EPS of -$0.01, missing the $0.00 consensus estimate, with revenue not explicitly stated
May 12, 2026
MIXED
Press
6/10
Mereo BioPharma reported its 2025 financial results, showing a narrower net loss of $41.9 million compared to $43.3 mill
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Rubric Capital Management LP | $5.1M | — |
| BANK OF AMERICA CORP | $2.7M | DOUBLED |
| MARSHALL WACE, LLP | $226.7K | — |
| CITADEL ADVISORS LLC | $127.7K | DOUBLED |
| GROUP ONE TRADING LLC | $110.8K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 26, 2026 | Jacquet Pierre | A | $0.00 |
| Feb 26, 2026 | Jacquet Pierre | A | $0.00 |
| Feb 26, 2026 | Bender Jeremy | A | $0.00 |
| Feb 26, 2026 | Bender Jeremy | A | $0.00 |
| Feb 26, 2026 | PAKIANATHAN DEEPIKA | A | $0.00 |
Reddit Sentiment
75°
Bullish
Bearish
Neutral
Bullish
22 institutional holders with $8.6M total value (26,199,273 shares) as of 2026-Q1. Top holders: Rubric, BANK, MARSHALL. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Rubric Capital Management LP | 15,307,347 | $5.1M | 58.4% | — |
| 2 | BANK OF AMERICA CORP /DE/ | 8,195,287 | $2.7M | 31.3% | DOUBLED +32048.5% |
| 3 | MARSHALL WACE, LLP | 686,987 | $226.7K | 2.6% | — |
| 4 | CITADEL ADVISORS LLC | 387,000 | $127.7K | 1.5% | DOUBLED +317.0% |
| 5 | GROUP ONE TRADING LLC | 335,827 | $110.8K | 1.3% | DOUBLED +223.3% |
| 6 | BlackRock, Inc. | 302,991 | $100.0K | 1.2% | TRIM -29.6% |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 203,600 | $67.2K | 0.8% | — |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 195,920 | $64.7K | 0.7% | — |
| 9 | TWO SIGMA INVESTMENTS, LP | 187,839 | $62.0K | 0.7% | TRIM -51.7% |
| 10 | STATE STREET CORP | 133,379 | $44.0K | 0.5% | DOUBLED +195.3% |
| 11 | CITADEL ADVISORS LLC | 67,800 | $22.4K | 0.3% | DOUBLED +317.0% |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 48,400 | $16.0K | 0.2% | NEAR_EXIT -75.1% |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 44,400 | $14.7K | 0.2% | — |
| 14 | Independent Advisor Alliance | 35,227 | $11.6K | 0.1% | — |
| 15 | Centiva Capital, LP | 25,000 | $8.3K | 0.1% | — |
| 16 | RHUMBLINE ADVISERS | 19,572 | $6.5K | 0.1% | DOUBLED +109.9% |
| 17 | MORGAN STANLEY | 16,425 | $5.4K | 0.1% | NEAR_EXIT -98.7% |
| 18 | BARCLAYS PLC | 2,496 | $824.00 | 0.0% | — |
| 19 | Rockefeller Capital Management L.P. | 2,000 | $660.00 | 0.0% | — |
| 20 | Allworth Financial LP | 1,500 | $495.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 25,492 | 8,195,287 | +32048.5% | $2.7M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 194,371 | 48,400 | -75.1% | $16.0K | 2026-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 1,273,785 | 16,425 | -98.7% | $5.4K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 3,346,347 | 1,273,785 | -61.9% | $530.8K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 1,088,096 | 525,125 | -51.7% | $218.8K | 2025-Q4 |
| GROUP ONE TRADING LLC | DOUBLED | 136,588 | 441,636 | +223.3% | $184.0K | 2025-Q4 |
| BlackRock, Inc. | TRIM | 444,004 | 312,613 | -29.6% | $130.3K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 590,871 | 194,371 | -67.1% | $81.0K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 438,622 | 25,492 | -94.2% | $10.6K | 2025-Q4 |
| RHUMBLINE ADVISERS | DOUBLED | 9,122 | 19,146 | +109.9% | $8.0K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 230 | 1,737 | +655.2% | $724.00 | 2025-Q4 |
| JANUS HENDERSON GROUP PLC | EXIT | 16,290,130 | 0 | -100.0% | $0.00 | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 785,377 | 3,346,347 | +326.1% | $6.9M | 2025-Q3 |
| CITADEL ADVISORS LLC | DOUBLED | 760,659 | 3,171,632 | +317.0% | $6.5M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 659,158 | 1,088,096 | +65.1% | $2.2M | 2025-Q3 |
| UBS Group AG | DOUBLED | 373,505 | 970,667 | +159.9% | $2.0M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,480,471 | 590,871 | -60.1% | $1.2M | 2025-Q3 |
| Hudson Bay Capital Management LP | TRIM | 450,000 | 265,000 | -41.1% | $545.9K | 2025-Q3 |
| STATE STREET CORP | DOUBLED | 44,942 | 132,701 | +195.3% | $273.4K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 245,206 | 659,158 | +168.8% | $1.8M | 2025-Q2 |
| UBS Group AG | TRIM | 932,021 | 373,505 | -59.9% | $1.0M | 2025-Q2 |
| NEOS Investment Management LLC | NEAR_EXIT | 654,666 | 102,583 | -84.3% | $278.0K | 2025-Q2 |
| Point72 Asset Management, L.P. | ADD | 35,816 | 59,200 | +65.3% | $160.4K | 2025-Q2 |
| RHUMBLINE ADVISERS | ADD | 6,588 | 9,878 | +49.9% | $26.8K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 1,230 | 230 | -81.3% | $622.00 | 2025-Q2 |
13 unique insiders with 19 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Jacquet Pierre | Director | AWARD | 66,000 | — | — |
| Feb 26, 2026 | Jacquet Pierre | Director | AWARD | 106,848 | — | — |
| Feb 26, 2026 | Bender Jeremy | Director | AWARD | 66,000 | — | — |
| Feb 26, 2026 | Bender Jeremy | Director | AWARD | 117,533 | — | — |
| Feb 26, 2026 | PAKIANATHAN DEEPIKA | Director | AWARD | 66,000 | — | — |
| Feb 26, 2026 | Jenkins Annalisa | Director | AWARD | 66,000 | — | — |
| Feb 26, 2026 | WYZGA MICHAEL S | Director | AWARD | 66,000 | — | — |
| Feb 26, 2026 | Jenkins Annalisa | Director | AWARD | 106,848 | — | — |
| Feb 26, 2026 | Yoskowitz Marc J | Director | AWARD | 66,000 | — | — |
| Feb 26, 2026 | Yoskowitz Marc J | Director | AWARD | 96,163 | — | — |
| Feb 26, 2026 | Shames Daniel | Director | AWARD | 66,000 | — | — |
| Feb 26, 2026 | Shames Daniel | Director | AWARD | 96,163 | — | — |
| Feb 26, 2026 | Ekblom Anders | Director | AWARD | 66,000 | — | — |
| Feb 26, 2026 | Ekblom Anders | Director | AWARD | 133,560 | — | — |
| Feb 1, 2026 | Fox Christine Ann | Chief Financial Officer | AWARD | 315,750 | — | — |
| Feb 1, 2026 | Lewicki John A. | Chief Scientific Officer | AWARD | 139,913 | — | — |
| Feb 1, 2026 | Scots-Knight Denise | Chief Executive Officer | AWARD | 1,035,000 | — | — |
| Feb 1, 2026 | Hughes-Wilson Alexandra | See Remarks | AWARD | 183,750 | — | — |
| Feb 1, 2026 | Sermon Charles | General Counsel | AWARD | 315,750 | — | — |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
Current analyst consensus: Buy (71% buy). Based on 14 analysts: 5 strong buy, 5 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$1.73 mean target
+467.7% upside
Strong Buy (3.00)
$0.4982 Low
$2.98 High
| Metric | Value |
|---|---|
| Current Price | $0.3050 |
| Target Low | $0.4982 |
| Target Mean | $1.73 |
| Target Median | $1.48 |
| Target High | $2.98 |
| # Analysts | 6 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.01 | $-0.01 | $0.00 | 62.5% | — | — | $0.0B | 133.5% | 5 |
| Next Q 2026-09-30 |
$-0.01 | $-0.01 | $-0.01 | 7.9% | — | — | $0.0B | 0.0% | 5 |
| Current FY 2026-12-31 |
$-0.03 | $-0.04 | $-0.02 | 24.8% | — | 1↑ 1↓ | $0.0B | 133.7% | 5 |
| Next FY 2027-12-31 |
$-0.03 | $-0.04 | $0.01 | -0.5% | — | 1↑ 0↓ | $0.0B | 1567.3% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.006 | |
| 7d ago | $0.000 | -0.006 |
| 30d ago | $0.000 | -0.006 |
| 60d ago | $-0.004 | -0.002 |
| 90d ago | $-0.004 | -0.002 |
5 analyst firms have rated this stock: 0 upgrades, 3 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 12, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 23, 2026 | JP Morgan | DOWNGRADE | Overweight | Neutral |
| Jan 16, 2026 | BTIG | REITERATE | Buy | Buy |
| Jan 13, 2026 | Needham | MAINTAIN | Buy | Buy |
| Dec 30, 2025 | Jefferies | DOWNGRADE | Buy | Hold |
| Dec 29, 2025 | BTIG | MAINTAIN | Buy | Buy |
| Dec 29, 2025 | LifeSci Capital | DOWNGRADE | Outperform | Market Perform |
| Dec 22, 2025 | Needham | REITERATE | Buy | Buy |
| Dec 18, 2025 | BTIG | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 5 | 4 | 0 | 0 | 71% | |
| May 1, 2026 | 5 | 5 | 4 | 0 | 0 | 71% | |
| Apr 1, 2026 | 5 | 5 | 4 | 0 | 0 | 71% | |
| Mar 1, 2026 | 5 | 6 | 3 | 0 | 0 | 79% | |
| Feb 1, 2026 | 5 | 6 | 3 | 0 | 0 | 79% | |
| Jan 1, 2026 | 5 | 6 | 3 | 0 | 0 | 79% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
75°
Bullish
Bearish
Neutral
Bullish
4 mentions
4 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 2, 2026
short_volume
Short Volume: MREO — 60.3% short (3.0M / 5.0M)
Short: 3,027,630 | Exempt: 376,275 | TRF Vol: 5,019,059 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: MREO — 55.2% short (0.4M / 0.8M)
Short: 432,854 | Exempt: 9,999 | TRF Vol: 784,061 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: MREO — 60.3% short (0.4M / 0.7M)
Short: 441,565 | Exempt: 2,000 | TRF Vol: 732,404 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: MREO — 65.7% short (0.4M / 0.6M)
Short: 367,275 | Exempt: 50 | TRF Vol: 559,331 | Short Ratio: 65.7% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
<p align="justify">LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage bi
May 11, 2026
earnings_calendar
MREO Q1 2026 Earnings Scheduled — 2026-05-11
Apr 23, 2026
short_volume
Short Volume: MREO — 59.2% short (0.4M / 0.7M)
Short: 434,016 | Exempt: 20,202 | TRF Vol: 733,648 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: MREO — 58.5% short (0.4M / 0.8M)
Short: 449,713 | Exempt: 0 | TRF Vol: 768,189 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: MREO — 55.4% short (1.7M / 3.1M)
Short: 1,688,796 | Exempt: 0 | TRF Vol: 3,050,140 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
short_volume
Short Volume: MREO — 56.8% short (0.3M / 0.6M)
Short: 349,211 | Exempt: 0 | TRF Vol: 614,466 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
Apr 9, 2026
short_volume
Short Volume: MREO — 56.1% short (0.3M / 0.5M)
Short: 284,836 | Exempt: 300 | TRF Vol: 508,107 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
short_volume
Short Volume: MREO — 63.7% short (0.6M / 1.0M)
Short: 616,203 | Exempt: 635 | TRF Vol: 967,624 | Short Ratio: 63.7% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
earnings_calendar
MREO Q4 2025 Earnings After Market Close — 2026-03-23
Mar 19, 2026
earnings
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
<p align="center"><em>Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing</em></p>